Evidence map›Paper›PMID 31515429›Full record

ArticleBMJ open2019

Burden of visual impairment associated with eye diseases: exploratory survey of 298 Chinese patients.

Xiaodong Guan, Mengyuan Fu, Fanghui Lin, Dawei Zhu, Daniel Vuillermin, Luwen Shi

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Burden of visual impairment in mainland China: the Handan Eye Study and Beijing Eye Study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xiaodong GuanSchool of Pharmaceutical Sciences, Peking University, Beijing, China.
Mengyuan FuSchool of Pharmaceutical Sciences, Peking University, Beijing, China.
Fanghui LinInternational Research Center for Medicinal Administration, Peking University, Beijing, China.
Dawei ZhuInternational Research Center for Medicinal Administration, Peking University, Beijing, China.
Daniel VuillerminSchool of Health Humanities, Peking University, Beijing, China.
Luwen ShiSchool of Pharmaceutical Sciences, Peking University, Beijing, China shiluwen211@163.com.ORCID 0000-0003-2683-6685
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo explore the economic burden, prevalence of catastrophic healthcare expenditure (CHE) and the quality of life (QoL) of Chinese patients with visual impairment (VI) associated with eye diseases.

designA questionnaire survey from March to May 2016 by structured face-to-face interviews of patients with VI.

participants302 patients who were diagnosed with moderate VI or worse in both eyes (visual acuity <6/18) were included, and 298 patients (98.7%) who completed the survey questionnaires were eligible for the study. OUTCOME MEASURES: The economic burden was estimated by calculating participants' direct costs covered in 2015 and the definition of CHE was out-of-pocket (OOP) costs exceeding 30% of annual household income. QoL was weighed by health utility value using time-trade-off valuation techniques.

resultsAnnual average direct costs per patient caused by VI were US$6988.6±US$10 834.3, and 70.3% were direct medical costs of which only 26.9% were reimbursable by medical insurance. 32.2% of households that suffered from CHE, in particular, were less wealthy patients with VI living in rural areas and without medical insurance. The health utility value was rated at 0.65 on average, and patients with VI aged 51-57, living alone and insured by commercial medical insurance had relatively less QoL.

conclusionOur study explored the economic burden and QoL of VI associated with patients with eye diseases in China, indicating a substantial economic burden and poor QoL. Preferential medical insurance policies should be designed in relation to people with VI to further reduce the health inequalities, avoid CHE and promote QoL.

Indexed as

Cost of IllnessEye DiseasesQuality of LifeVisual AcuityChinaCosts and Cost AnalysisFemaleHumansMaleMiddle AgedNeeds AssessmentPrevalenceSeverity of Illness IndexSocioeconomic FactorsSurveys and QuestionnairesVision Disorderscatastrophic healthcare expenditureeconomic burdenquality of lifevisual impairment

Identifiers

PMID31515429
PMCPMC6747637
OpenAlexW2972805264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.